GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (FRA:RQ1) » Definitions » Asset Turnover

Rosetta Genomics (FRA:RQ1) Asset Turnover : 0.09 (As of Jun. 2017)


View and export this data going back to 2014. Start your Free Trial

What is Rosetta Genomics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Rosetta Genomics's Revenue for the three months ended in Jun. 2017 was €0.77 Mil. Rosetta Genomics's Total Assets for the quarter that ended in Jun. 2017 was €8.43 Mil. Therefore, Rosetta Genomics's Asset Turnover for the quarter that ended in Jun. 2017 was 0.09.

Asset Turnover is linked to ROE % through Du Pont Formula. Rosetta Genomics's annualized ROE % for the quarter that ended in Jun. 2017 was -285.46%. It is also linked to ROA % through Du Pont Formula. Rosetta Genomics's annualized ROA % for the quarter that ended in Jun. 2017 was -87.43%.


Rosetta Genomics Asset Turnover Historical Data

The historical data trend for Rosetta Genomics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Asset Turnover Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.07 0.44 0.55

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.02 0.16 0.17 0.09

Competitive Comparison of Rosetta Genomics's Asset Turnover

For the Diagnostics & Research subindustry, Rosetta Genomics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Asset Turnover falls into.



Rosetta Genomics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Rosetta Genomics's Asset Turnover for the fiscal year that ended in Dec. 2016 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2016 )/( (Total Assets (A: Dec. 2015 )+Total Assets (A: Dec. 2016 ))/ count )
=8.754/( (20.584+11.339)/ 2 )
=8.754/15.9615
=0.55

Rosetta Genomics's Asset Turnover for the quarter that ended in Jun. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2017 )/( (Total Assets (Q: Dec. 2016 )+Total Assets (Q: Jun. 2017 ))/ count )
=0.774/( (11.339+5.524)/ 2 )
=0.774/8.4315
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Rosetta Genomics  (FRA:RQ1) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Rosetta Genomics's annulized ROE % for the quarter that ended in Jun. 2017 is

ROE %**(Q: Jun. 2017 )
=Net Income/Total Stockholders Equity
=-7.372/2.5825
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-7.372 / 3.096)*(3.096 / 8.4315)*(8.4315/ 2.5825)
=Net Margin %*Asset Turnover*Equity Multiplier
=-238.11 %*0.3672*3.2649
=ROA %*Equity Multiplier
=-87.43 %*3.2649
=-285.46 %

Note: The Net Income data used here is four times the quarterly (Jun. 2017) net income data. The Revenue data used here is four times the quarterly (Jun. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Rosetta Genomics's annulized ROA % for the quarter that ended in Jun. 2017 is

ROA %(Q: Jun. 2017 )
=Net Income/Total Assets
=-7.372/8.4315
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-7.372 / 3.096)*(3.096 / 8.4315)
=Net Margin %*Asset Turnover
=-238.11 %*0.3672
=-87.43 %

Note: The Net Income data used here is four times the quarterly (Jun. 2017) net income data. The Revenue data used here is four times the quarterly (Jun. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Rosetta Genomics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (FRA:RQ1) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Rosetta Genomics (FRA:RQ1) Headlines

No Headlines